Alyeska Investment Group L.P. Raises Holdings in Artiva Biotherapeutics, Inc. $ARTV

Key Points

• Alyeska Investment Group increased its Artiva Biotherapeutics stake by 173.6% in the second quarter, ending with 273,615 shares worth approximately $2.65 million. Several other major investors, including 5AM Venture Management, Blue Owl Capital and BlackRock, also initiated positions.
• Analyst sentiment is broadly positive, with a consensus “Moderate Buy” rating and an average price target of $39, although one analyst maintains a sell rating. Recent targets range from $35 to $41.
• ARTV opened at $11.28, while the company reported a quarterly loss of $0.63 per share, in line with estimates. Insiders have been net buyers over the past quarter, acquiring nearly 2 million shares worth $16.2 million.

Alyeska Investment Group L.P. increased its holdings in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) by 173.6% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 273,615 shares of the company's stock after buying an additional 173,615 shares during the period. Alyeska Investment Group L.P. owned about 0.56% of Artiva Biotherapeutics worth $2,654,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of ARTV. Nantahala Capital Management LLC bought a new stake in Artiva Biotherapeutics during the 2nd quarter valued at $2,910,000. 5AM Venture Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the 2nd quarter worth $22,827,049. ADAR1 Capital Management LLC acquired a new stake in Artiva Biotherapeutics in the second quarter worth about $1,151,000. Blue Owl Capital Holdings LP purchased a new stake in Artiva Biotherapeutics during the 2nd quarter worth approximately $8,483,000. Finally, BlackRock Inc. purchased a new position in Artiva Biotherapeutics in the 2nd quarter worth $6,739,000.

Analysts Set New Price Targets

ARTV has been the subject of several research reports. Wall Street Zen upgraded shares of Artiva Biotherapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 8th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Artiva Biotherapeutics in a research report on Tuesday, July 21st. Needham & Company LLC reaffirmed a "buy" rating and set a $41.00 target price on shares of Artiva Biotherapeutics in a report on Monday, June 8th. HC Wainwright increased their price target on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a "buy" rating in a report on Friday, May 8th. Finally, Wedbush boosted their target price on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an "outperform" rating in a report on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $39.00.

Insider Transactions at Artiva Biotherapeutics

In related news, insider Subhashis Banerjee sold 8,222 shares of Artiva Biotherapeutics stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $12.01, for a total value of $98,746.22. Following the completion of the transaction, the insider owned 142,047 shares in the company, valued at approximately $1,705,984.47. The trade was a 5.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ra Capital Management, L.P. bought 24,944 shares of the business's stock in a transaction that occurred on Friday, July 31st. The shares were acquired at an average cost of $9.93 per share, for a total transaction of $247,693.92. Following the completion of the purchase, the director owned 17,329,570 shares in the company, valued at $172,082,630.10. This trade represents a 0.14% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired 1,965,251 shares of company stock worth $16,188,035 over the last quarter. Insiders own 1.80% of the company's stock.

Artiva Biotherapeutics Stock Down 0.2%

ARTV opened at $11.28 on Wednesday. Artiva Biotherapeutics, Inc. has a 52 week low of $2.22 and a 52 week high of $14.53. The business has a fifty day simple moving average of $10.45 and a 200-day simple moving average of $8.63. The firm has a market cap of $551.48 million, a P/E ratio of -3.42 and a beta of 2.18.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.63). Sell-side analysts expect that Artiva Biotherapeutics, Inc. will post -2.62 earnings per share for the current year.

Artiva Biotherapeutics Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company's proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva's pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source